Both MHC II+CD11c− APCs and DCs were significantly increased in local (Fig. 6a, b) and distant (Fig. 6c, d) tumors in ZD55-IL-24-treated mice, but not in anti-PD-1-treated mice, indicating that ZD55-IL-24 was able to improve tumor immune recognition in both local and distant tumors, while PD-1 blockade failed to achieve this effect. Here, PDCD1 is linked to neoplasm.